R(-) salmeterol patent filed today. This is Glaxo's Serevent, a 2x a day bronchodilator. Serevent sales are about $700m a year, but I believe the US patent only expires in 2008, so unless they do a deal with Glaxo this isn't of short term significance.
BTW, the slides from the NY investor lunch are on the SEPR web site. Not much change from the previous set of slides, except in the NCE section, and one or two target dates that have slipped a year.
(The "delta" of these sort of presentations (i.e., what has changed) is what you want to focus on, BTW. It's generally more revealing than what they actually say).
Peter
United States Patent 5,919,827
Barberich , et al. July 6, 1999
--------------------------------------------------------------------------------
Method for treating asthma using optically pure R(-) salmeterol
Abstract
The optically pure R(-) isomer of salmeterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of salmeterol for treating asthma while minimizing toxicity and other side effects associated with salmeterol.
--------------------------------------------------------------------------------
Inventors: Barberich; Timothy J. (Concord, MA); Young; James W. (Palo Alto, CA)
Assignee: Sepracor Inc. (Marlborough, MA)
Appl. No.: 992376
Filed: December 17, 1997
U.S. Class: 514/651; 514/649
Intern'l Class: A61K 031/135
Field of Search: 514/651,649
--------------------------------------------------------------------------------
References Cited [Referenced By]
--------------------------------------------------------------------------------
U.S. Patent Documents
4992474 Feb., 1991 Skidmore et al. 514/653.
Foreign Patent Documents
0422889 Apr., 1991 EP.
2140800 Dec., 1984 GB.
Other References
J. Morley et al., Effects of (+) and Racemic Salmutamol on Airway Responses in the Guinnea-Pig, BR. J. Pharmaca., 104, Proc. Supp. (1991).
Larsson, Chem. Abst. 114(3): 1694lr; "Long-term Studies on Long Acting Sympathomimetics", Lung 168 (Suppl), 22-24 (1990).
Johnson, Chem. Abst. 114(3): 16944u: "The Pharmacology of Salmeterol", Lung 168 (Suppl.) 115-119 (1990).
Chem. Abst. 114 (7): 55571q; Brittain, "Approaches to a Long-Acting, Selective beta.sub.2 -adrenoceptor Stimulant", Lung 168 (Suppl.), 111-114 (1990).
World Patent Index Acc. No.: 84-264874/43; DE 3414752, Oct. 18, 1984, Skidmore et al., New Phenyl Amino Ethanol Derivative.
Jamali et al., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls", J. Pharma. Sci. 78(9), 695-711 (1989).
Primary Examiner: Jarvis; William R. A.
Attorney, Agent or Firm: Heslin & Rothenberg, P.C.
--------------------------------------------------------------------------------
Parent Case Text
--------------------------------------------------------------------------------
RELATED APPLICATIONS
This application is a continuation of Ser. No. 08/430,746, filed Apr. 28, 1995, now abandoned, which is a continuation of Ser. No. 08/008,526, filed Jan. 25, 1993, now abandoned, which is a Continuation-In-Part of U.S. Ser. No. 07/551,622 filed Jul. 11, 1990, now abandoned. The teachings of this application are incorporated herein by reference.
--------------------------------------------------------------------------------
Claims
--------------------------------------------------------------------------------
1. A method of treating asthma in an individual with salmeterol, while reducing toxicity and other side effects associated with salmeterol, comprising administering to the individual a quantity of an optically pure R(-) isomer of salmeterol sufficient to result in bronchodilation, said R(-) isomer being substantially free of its S(+) isomer.
|
